Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCE: DKrd vs KRD vs VRD in Newly Diagnosed Multiple Myeloma
NCT04268498Phase 2Active, not recruiting
- Sponsor
- University of Miami
- Start
- Feb 2020
- Primary completion
- Feb 2027
- Modality
- Reversible Covalent Inhibitors, Monoclonal Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab, carfilzomib in multiple myeloma (MM), sponsored by University of Miami. Started Feb 2020; status: active, not recruiting.
02
Drugs
daratumumabcarfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04268498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04268498.